Early Prevention of Obesity: Tackling from Conception

By Melike Belenli Gümüş

October 16, 2024

A recent article discusses the potential for monitoring obesity from the earliest stages of development, including during the fetal period in the womb. This proactive approach highlights the importance of addressing obesity right from conception in order to achieve early prevention of obesity.

Early Prevention of Obesity

The article highlights research focused on the early prevention of obesity through a project named “eprObes” (Early Prevention of Obesity). This initiative aims to implement interventions that could significantly lower the risk of obesity later in life.

Factors Influencing Obesity

The study aims to identify and understand the various factors that contribute to obesity, starting from the pre-conception period and continuing through pregnancy and early childhood. These factors include genetic, environmental, and lifestyle influences that can affect the development of obesity in children.

Importance of Prenatal Care

The research emphasises the critical role of prenatal care in monitoring both the mother’s and the fetus’s health. Preventive measures during pregnancy could be key in reducing the incidence of obesity later in life.

Long-Term Health Implications

By addressing obesity at its earliest roots, the study aims to lower the risk of long-term health complications associated with obesity, such as metabolic syndrome, diabetes, and other related health issues.

Overall, the article indicates a shift towards a more proactive and preventive approach to managing obesity, starting at the earliest possible stage of human development. This new focus could lead to healthier outcomes for future generations.

Reference url

Recent Posts

Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Management

By João L. Carapinha

March 3, 2026

Tirzepatide Cost Effectiveness in UK T2D Care Evaluating tirzepatide cost effectiveness reveals significant advantages over semaglutide 1 mg for patients with type 2 diabetes (T2D) inadequately controlled on metformin, based on a
HERNEXEOS Lung Cancer Treatment: First FDA Approval for HER2-Mutant NSCLC

By HEOR Staff Writer

March 2, 2026

FDA Greenlights HERNEXEOS Lung Cancer Treatment as First-Line Option HERNEXEOS lung cancer treatment (zongertinib tablets), developed by
KEYTRUDA Padcev MIBC Survival: New Era in Treatment Revealed by KEYNOTE-B15 Trial Results
KEYTRUDA Padcev MIBC Survival Breakthrough in Cisplatin-Eligible Patients KEYTRUDA Padcev MIBC Survival benefits shone in the Phase 3 KEYNOTE-B15 trial, where perioperative KEYTRUDA (pembrolizumab) plus Padce...